Placebo by Proxy in Neonatal Randomized Controlled Trials: Does It Matter?
AbstractPlacebo effects emerging from the expectations of relatives, also known as placebo by proxy, have seldom been explored. The aim of this study was to investigate whether in a randomized controlled trial (RCT) there is a clinically relevant difference in long-term outcome between very preterm infants whose parents assume that verum (PAV) had been administered and very preterm infants whose parents assume that placebo (PAP) had been administered. The difference between the PAV and PAP infants with respect to the primary outcome–IQ at 5 years of age–was considered clinically irrelevant if the confidence interval (CI) for the mean difference resided within our pre-specified ±5-point equivalence margins. When adjusted for the effects of verum/placebo, socioeconomic status (SES), head circumference and sepsis, the CI was [−3.04, 5.67] points in favor of the PAV group. Consequently, our study did not show equivalence between the PAV and PAP groups, with respect to the pre-specified margins of equivalence. Therefore, our findings suggest that there is a small, but clinically irrelevant degree to which a preterm infant’s response to therapy is affected by its parents’ expectations, however, additional large-scale studies are needed to confirm this conjecture. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Burkart, T.L.; Kraus, A.; Koller, B.; Natalucci, G.; Latal, B.; Fauchère, J.-C.; Bucher, H.U.; Rüegger, C.M.; for the Swiss EPO Neuroprotection Trial Group. Placebo by Proxy in Neonatal Randomized Controlled Trials: Does It Matter? Children 2017, 4, 43.
Burkart TL, Kraus A, Koller B, Natalucci G, Latal B, Fauchère J-C, Bucher HU, Rüegger CM, for the Swiss EPO Neuroprotection Trial Group. Placebo by Proxy in Neonatal Randomized Controlled Trials: Does It Matter? Children. 2017; 4(6):43.Chicago/Turabian Style
Burkart, Tiziana L.; Kraus, Andrea; Koller, Brigitte; Natalucci, Giancarlo; Latal, Beatrice; Fauchère, Jean-Claude; Bucher, Hans Ulrich; Rüegger, Christoph M.; for the Swiss EPO Neuroprotection Trial Group. 2017. "Placebo by Proxy in Neonatal Randomized Controlled Trials: Does It Matter?" Children 4, no. 6: 43.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.